EPIC Act of 2025
Summary
The EPIC Act of 2025 would extend small-molecule drug exclusivity before Medicare price negotiation from 7 to 11 years for drugs approved after 2028. Despite sector-wide 30-day declines ($MRK -7.18%, $GSK -5.02%, $PFE -4.24%), the bill's early-stage status (referred to Senate Finance Committee) and long legislative path mean no near-term revenue impact. The structural beneficiary is clear: small-molecule-focused pharma pipelines gain 4 additional years of un-negotiated pricing.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.EPIC Act equalizes small-molecule and biologic negotiation periods at 11 years starting 2028.
- 2.No direct federal spending—this is a regulatory delay of price negotiation, not a funding bill.
- 3.Primary beneficiaries are pharma companies with post-2028 small-molecule pipelines: MRK, PFE, GSK.
- 4.Bill is very early-stage (referred to committee, 7 cosponsors)—long legislative path ahead.
- 5.Current stock prices for MRK, PFE, GSK are all down 4-7% over 30 days, reflecting broader sector pressures unrelated to this bill.
Market Implications
Despite the 30-day declines in $MRK (-7.18% to $111.66), $PFE (-4.24% to $26.89), and $GSK (-5.02% to $52.42), the EPIC Act is a material structural positive for small-molecule pharma. Investors should view the current pullback as a potential entry point if legislative momentum builds. However, the bill is early-stage, and any near-term bounce would be speculative. Watch for: Senate Finance Committee markup, companion House bill introduction, and CBO score. The 2028 implementation date means no revenue impact for at least 2 years post-enactment, limiting near-term catalysts.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Extends the minimum market approval period before a small-molecule drug qualifies for Medicare price negotiation from 7 to 11 years, effective for initial price applicability year 2028 and later.
Who must act
Centers for Medicare & Medicaid Services (CMS) under the Medicare Drug Price Negotiation Program
What happens
Small-molecule drugs approved after 2028 will have an additional 4 years of market exclusivity before facing mandatory price negotiation with CMS, delaying potential revenue erosion from government-set prices.
Stock impact
Merck's pipeline of small-molecule drugs (e.g., Keytruda is a biologic, but small-molecule candidates in oncology, cardiometabolic, and infectious disease) could see extended high-margin revenue windows. Merck had ~$12B in R&D spend in FY2025; small-molecule R&D is a significant portion. Delay of negotiation by 4 years per approved drug could preserve hundreds of millions in peak-year revenue per asset.
What the bill does
Extends the minimum market approval period before a small-molecule drug qualifies for Medicare price negotiation from 7 to 11 years, effective for initial price applicability year 2028 and later.
Who must act
Centers for Medicare & Medicaid Services (CMS) under the Medicare Drug Price Negotiation Program
What happens
Small-molecule drugs approved after 2028 will have an additional 4 years of market exclusivity before facing mandatory price negotiation with CMS, delaying potential revenue erosion from government-set prices.
Stock impact
Pfizer has a robust small-molecule pipeline spanning oncology, inflammation, vaccines (small-molecule adjuvants), and rare disease. Approximately 60% of Pfizer's revenue comes from small molecules. Delaying negotiation by 4 years per asset could protect $500M-$2B in revenue per blockbuster over the extended exclusivity window.
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Protecting Americans from Unsafe Drugs Act of 2026
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
American Innovation and R&D Competitiveness Act of 2025
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Skinny Labels, Big Savings Act
Lowering Drug Costs for American Families Act
Most Favored Patient Act of 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.